A Winning United Way Campaign
Last fall the Athens site participated in the 2018 United Way Campaign with a goal to pledge $10,000.00 to support 18 agencies in Northeast Georgia…
AXIM Biotechnologies Advances Dronabinol Therapeutic Equivalence Program Through Purchase Agreement With Noramco
AXIM® Biotechnologies, Inc. announced that it has reached a long-term purchase agreement for pharmaceutical-grade dronabinol with Noramco, a global leader in the production of controlled substances for the pharmaceutical industry.
Noramco Competes in 10th Consecutive American Odyssey Relay Run for Charity
Noramco competed in its 10th consecutive American Odyssey Relay run for charity. A team of 12 runners embarked upon a journey from Gettysburg, PA to Washington D.C., spanning 200 miles in a total time of 29 hours and 18 minutes.
Say Hello to Justin Mills
Quality is always evaluating improvements and efficiencies. No one understands that better than Justin Mills, our Quality Systems Supervisor. Joining Noramco 15 years ago, initially as a Quality Control Analyst, he continues to raise the bar in quality.
Noramco and SPI Pharma sign agreement to develop ready-to-implement, patient-friendly formulations for pharmaceutical manufacturers
Noramco and SPI Pharma have signed an agreement to develop and license a set of “value-added” formulation packages for global pharmaceutical manufacturers…
Noramco adds 23 compounds to analytical reference standards catalogue
Noramco announced the addition of 23 new compounds to its analytical reference standards catalog – compounds pharmaceutical product developers require to validate product quality and to verify the integrity of production systems…
Noramco at DCAT Week 2018
Meet Noramco at DCAT Week ’18, to be held March 19-22, New York, NY. Come talk to us about Cannabinoids, Clinical and Custom Solutions, Product Conversion, and what we are doing in the ADHD Space. DCAT Week is the premier business development event for companies engaged in pharmaceutical development…
Noramco introduces controlled substance development solutions at CPhI Worldwide
Noramco is integrating its API development offering to include all of the technologies and services that generic and branded pharmaceutical producers require to advance solutions to market. The specialty API producer today introduced a comprehensive…
Noramco and SPI Pharma sign letter of intent to develop formulation solution packages
Noramco, a global leader in the manufacture and supply of controlled substance active pharmaceutical ingredients, and SPI Pharma, a global leader in the manufacture and supply of functional excipient platforms and drug development services…
Noramco introduces a turnkey approach to cannabinoid APIs at CPhI Worldwide
Noramco is moving forward with a broad offering of clinical- to commercial-scale cannabinoid APIs for branded and generic pharmaceuticals. The comprehensive offering includes everything a drug manufacturer requires to advance cannabinoid-based APIs to finished dosage forms.